Intrinsa

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
18-06-2012
Summary of Product characteristics Summary of Product characteristics (SPC)
18-06-2012
Public Assessment Report Public Assessment Report (PAR)
18-06-2012

Active ingredient:

Тестостеронът

Available from:

Warner Chilcott UK Ltd.

ATC code:

G03BA03

INN (International Name):

testosterone

Therapeutic group:

Полови хормони и слиза на половата система,

Therapeutic area:

Сексуални дисфункции, психологически

Therapeutic indications:

Intrinsa е показан за лечение на сексуално разстройство hypoactive желание (HSDD) в двустранно oophorectomised и hysterectomised (оперативно индуцираната менопауза) жени получаване съпътстващо естроген терапия.

Product summary:

Revision: 6

Authorization status:

Отменено

Authorization date:

2006-07-28

Patient Information leaflet

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт, който вече не е
разрешен за употреба
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Intrinsa 300 микрограма/24 часа
трансдермален пластир
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
_ _
Всеки пластир от 28 cm
2
съдържа 8,4 mg тестостерон (testosterone) и
осигурява 300 микрограма
тестостерон за 24 часа.
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Трансдермален пластир
Тънък, прозрачен, елипсовиден
трансдермален пластир от матричен
тип, състоящ се от три
слоя: прозрачен поддържащ филм,
адхезивен матричен слой с лекарството
и защитно
отстраняващо се покритие, което се
маха преди прилагане. Върху всяка
страна на пластира е
отпечатано „T001”.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Intrinsa е показана за лечение на
разстройство, свързано с намалено
желание за полово
общуване (НЖПО), при жени с двустранна
овариектомия и хистеректомия
(хирургично
индуцирана менопауза), получаващи
едновременно естрогенна терапия.
4.2
ДОЗИРОВКА И НАЧИН НА ПРИЛОЖЕНИЕ
Дозировка
Препоръчителната дневна доза
тестостерон е 300 микрограма. Тя се
постига чрез прилагане на
пластир два пъти
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт, който вече не е
разрешен за употреба
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Intrinsa 300 микрограма/24 часа
трансдермален пластир
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
_ _
Всеки пластир от 28 cm
2
съдържа 8,4 mg тестостерон (testosterone) и
осигурява 300 микрограма
тестостерон за 24 часа.
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Трансдермален пластир
Тънък, прозрачен, елипсовиден
трансдермален пластир от матричен
тип, състоящ се от три
слоя: прозрачен поддържащ филм,
адхезивен матричен слой с лекарството
и защитно
отстраняващо се покритие, което се
маха преди прилагане. Върху всяка
страна на пластира е
отпечатано „T001”.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Intrinsa е показана за лечение на
разстройство, свързано с намалено
желание за полово
общуване (НЖПО), при жени с двустранна
овариектомия и хистеректомия
(хирургично
индуцирана менопауза), получаващи
едновременно естрогенна терапия.
4.2
ДОЗИРОВКА И НАЧИН НА ПРИЛОЖЕНИЕ
Дозировка
Препоръчителната дневна доза
тестостерон е 300 микрограма. Тя се
постига чрез прилагане на
пластир два пъти
                                
                                Read the complete document

Similar products

Active ingredient Тестостеронът

Тестостеронът

ATC code G03BA03

G03BA03

Marketed by Warner Chilcott UK Ltd.

Warner Chilcott UK Ltd.

INN (International Name) testosterone

testosterone

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 18-06-2012
Summary of Product characteristics Summary of Product characteristics Spanish 18-06-2012
Public Assessment Report Public Assessment Report Spanish 18-06-2012
Patient Information leaflet Patient Information leaflet Czech 18-06-2012
Summary of Product characteristics Summary of Product characteristics Czech 18-06-2012
Public Assessment Report Public Assessment Report Czech 18-06-2012
Patient Information leaflet Patient Information leaflet Danish 18-06-2012
Summary of Product characteristics Summary of Product characteristics Danish 18-06-2012
Public Assessment Report Public Assessment Report Danish 18-06-2012
Patient Information leaflet Patient Information leaflet German 18-06-2012
Summary of Product characteristics Summary of Product characteristics German 18-06-2012
Public Assessment Report Public Assessment Report German 18-06-2012
Patient Information leaflet Patient Information leaflet Estonian 18-06-2012
Summary of Product characteristics Summary of Product characteristics Estonian 18-06-2012
Public Assessment Report Public Assessment Report Estonian 18-06-2012
Patient Information leaflet Patient Information leaflet Greek 18-06-2012
Summary of Product characteristics Summary of Product characteristics Greek 18-06-2012
Public Assessment Report Public Assessment Report Greek 18-06-2012
Patient Information leaflet Patient Information leaflet English 18-06-2012
Summary of Product characteristics Summary of Product characteristics English 18-06-2012
Public Assessment Report Public Assessment Report English 18-06-2012
Patient Information leaflet Patient Information leaflet French 18-06-2012
Summary of Product characteristics Summary of Product characteristics French 18-06-2012
Public Assessment Report Public Assessment Report French 18-06-2012
Patient Information leaflet Patient Information leaflet Italian 18-06-2012
Summary of Product characteristics Summary of Product characteristics Italian 18-06-2012
Public Assessment Report Public Assessment Report Italian 18-06-2012
Patient Information leaflet Patient Information leaflet Latvian 18-06-2012
Summary of Product characteristics Summary of Product characteristics Latvian 18-06-2012
Public Assessment Report Public Assessment Report Latvian 18-06-2012
Patient Information leaflet Patient Information leaflet Lithuanian 18-06-2012
Summary of Product characteristics Summary of Product characteristics Lithuanian 18-06-2012
Public Assessment Report Public Assessment Report Lithuanian 18-06-2012
Patient Information leaflet Patient Information leaflet Hungarian 18-06-2012
Summary of Product characteristics Summary of Product characteristics Hungarian 18-06-2012
Public Assessment Report Public Assessment Report Hungarian 18-06-2012
Patient Information leaflet Patient Information leaflet Maltese 18-06-2012
Summary of Product characteristics Summary of Product characteristics Maltese 18-06-2012
Public Assessment Report Public Assessment Report Maltese 18-06-2012
Patient Information leaflet Patient Information leaflet Dutch 18-06-2012
Summary of Product characteristics Summary of Product characteristics Dutch 18-06-2012
Public Assessment Report Public Assessment Report Dutch 18-06-2012
Patient Information leaflet Patient Information leaflet Polish 18-06-2012
Summary of Product characteristics Summary of Product characteristics Polish 18-06-2012
Public Assessment Report Public Assessment Report Polish 18-06-2012
Patient Information leaflet Patient Information leaflet Portuguese 18-06-2012
Summary of Product characteristics Summary of Product characteristics Portuguese 18-06-2012
Public Assessment Report Public Assessment Report Portuguese 18-06-2012
Patient Information leaflet Patient Information leaflet Romanian 18-06-2012
Summary of Product characteristics Summary of Product characteristics Romanian 18-06-2012
Public Assessment Report Public Assessment Report Romanian 18-06-2012
Patient Information leaflet Patient Information leaflet Slovak 18-06-2012
Summary of Product characteristics Summary of Product characteristics Slovak 18-06-2012
Public Assessment Report Public Assessment Report Slovak 18-06-2012
Patient Information leaflet Patient Information leaflet Slovenian 18-06-2012
Summary of Product characteristics Summary of Product characteristics Slovenian 18-06-2012
Public Assessment Report Public Assessment Report Slovenian 18-06-2012
Patient Information leaflet Patient Information leaflet Finnish 18-06-2012
Summary of Product characteristics Summary of Product characteristics Finnish 18-06-2012
Public Assessment Report Public Assessment Report Finnish 18-06-2012
Patient Information leaflet Patient Information leaflet Swedish 18-06-2012
Summary of Product characteristics Summary of Product characteristics Swedish 18-06-2012
Public Assessment Report Public Assessment Report Swedish 18-06-2012
Patient Information leaflet Patient Information leaflet Norwegian 18-06-2012
Summary of Product characteristics Summary of Product characteristics Norwegian 18-06-2012
Patient Information leaflet Patient Information leaflet Icelandic 18-06-2012
Summary of Product characteristics Summary of Product characteristics Icelandic 18-06-2012

Search alerts related to this product

Alerts Intrinsa Тестостеронът testosterone

Intrinsa Тестостеронът testosterone

View documents history

Documents history Documents history

Intrinsa